Skip to main content

Crystal form of the active pharmaceutical ingredient in a tablet

AppNote B-XRD1045: crystal form of the active pharmaceutical ingredient in a tablet


Many active pharmaceutical ingredients have multiple crystal forms, and it is known that solubility and bioavailability vary depending on the crystal form. In the drug manufacturing process, active ingredients may sometimes undergo a crystalline phase transition to another crystal form, due to factors such as heat, light, humidity or pressure, and there is a need to check what crystal form the ingredient is in, in its final product state. With optical systems employing the Bragg-Brentano focusing method, of the type generally used with powder X-ray diffractometry, measurement of the powdered sample is done with a reflection arrangement, but if a tablet is crushed into a powdered state, there are worries that transitions will occur due to the crushing, and it will be impossible to evaluate the original crystal form. In addition, if measurement is done with a reflection arrangement without crushing the tablet, it may be impossible to obtain internal information. Therefore, we analyzed a tablet non-destructively by using a convergent optical system enabling non-destructive/transmission measurement of tablets.

XRD products from Rigaku

Advanced state-of-the-art high-resolution XRD system powered by Guidance expert system software

Highly versatile multipurpose X-ray diffractometer with built-in intelligent guidance

New 6th-generation general purpose benchtop XRD system for phase i.d and phase quantification

High-performance, multi-purpose XRD system for applications ranging from R&D to quality control

Laboratory micro-spot XRD residual stress analysis with both iso- and side-inclination methods

2D X-ray detector with latest semiconductor technology designed for home lab diffractometers